Optibrium Enters Cheminformatics Collaboration with MSD
CAMBRIDGE, UK, 10 November 2020 – Optibrium™, a developer of software for drug discovery, today announced a collaboration with MSD tradename of Merck & Co., Inc, Kenilworth NJ USA. As part of the collaboration, MSD has adopted Optibrium’s StarDropTM software as a central component of their cheminformatics infrastructure.
The collaboration, between MSD and Optibrium will include integration of StarDrop with MSD’s in-house capabilities and the joint development of new tools, to improve cycle times, efficiency and productivity of the drug discovery process.
Dr Matthew Segall, Optibrium’s CEO, commented: “We are delighted to enter this collaboration to contribute to MSD’s world-leading cheminformatics infrastructure. We look forward to working together to advance new tools based around StarDrop to further refine our compound design platform.”
StarDrop is a complete package of fully integrated, elegant software for small molecule design, optimisation and data analysis. It supports researchers by quickly targeting high-quality chemistry in hit-to-lead and lead optimisation. StarDrop’s unique approach to multi-parameter optimisation combined with cutting-edge predictive modelling and generative chemistry capabilities helps to guide compound design decisions and will enable MSD’s researchers to explore new optimisation strategies.